15-valent pneumococcal conjugate vaccine
Trade name: VAXNEUVANCE
VaccineapprovedBreakthrough Therapy FDA
Approved
Jul 16, 2021
Clinical trial activity
44 trials · 10 clinical orgs · 1 marketing orgs
Phase 1
7
Phase 2
36
Phase 3
29
Phase 4
2
Earliest trial started Sep 1, 2009 (NCT01215175)
Timeline
Indications
Approved for
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Approval history
- approvedBreakthroughJul 16, 2021
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- v114
- v114
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06975878 | Phase 3 | May 22, 2025 | Sanofi |
| NCT06855160 | Phase 3 | Apr 17, 2025 | GlaxoSmithKline |
| NCT06806137 | Phase 3 | Mar 5, 2025 | GlaxoSmithKline |
| NCT06731374 | Phase 4 | Jan 31, 2025 | University of Liverpool, University of Oxford |
| NCT06740630 | Phase 3 | Dec 17, 2024 | GlaxoSmithKline |
| NCT06693895 | Phase 3 | Nov 19, 2024 | GlaxoSmithKline |
| NCT06271681 | Phase 4 | May 1, 2024 | Department of Veteran Affairs, Merck |
| NCT05939219 | N/A | Jul 1, 2023 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT05696080 | Phase 3 | Feb 13, 2023 | Merck |
| NCT05489328 | Phase 1 | Aug 15, 2022 | Pfizer |
| NCT05393037 | Phase 3 | Jul 13, 2022 | Merck |
| NCT05420961 | Phase 3 | Jul 12, 2022 | Merck |
| NCT05158140 | Phase 3 | Jan 12, 2022 | Merck |
| NCT06817187 | Phase 3 | Sep 16, 2021 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT04633226 | Phase 3 | Jan 7, 2021 | Merck |
| NCT04357522 | Phase 3 | Jul 31, 2020 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT04193215 | Phase 3 | Jun 17, 2020 | Merck |
| NCT04384107 | Phase 3 | Jun 9, 2020 | Merck |
| NCT04830358 | Phase 1 | May 28, 2020 | EuBiologics Co.,Ltd |
| NCT03921424 | Phase 3 | Sep 30, 2019 | Merck |
Showing 20 of 44 trials
Page 1 / 3
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 32 | 31 | 4 | 2009 |
| Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | For profit | 4 | 4 | 3 | 2019 |
| GlaxoSmithKline | For profit | 4 | 4 | 1 | 2024 |
| Department of Veteran Affairs | Government | 1 | 1 | 1 | 2024 |
| EuBiologics Co.,Ltd | For profit | 1 | 1 | 1 | 2020 |
| Government of China | Government | 1 | 0 | 1 | 2019 |
| Pfizer | For profit | 1 | 1 | 1 | 2022 |
| Sanofi | For profit | 1 | 1 | 1 | 2025 |
| University of Liverpool | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2025 |
10 organizations
Page 1 / 1